A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

This study is testing whether the combination of cadonilimab (a dual immune checkpoint drug targeting both PD-1 and CTLA-4) and lenvatinib (a targeted therapy blocking tumor blood vessel growth) can help patients with advanced clear cell kidney cancer (renal cell carcinoma) that has progressed after prior immunotherapy. **You may be eligible if...** - You are between 18 and 75 years old - You have advanced or metastatic clear cell kidney cancer confirmed by biopsy - Your cancer progressed after a prior immunotherapy-based treatment (second-line only) - You have measurable disease on imaging - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have previously received dual immunotherapy (a combination of two immune checkpoint drugs) - You have an active autoimmune disease or are on systemic steroids/immunosuppressants - You have uncontrolled heart disease - You are allergic to the study drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.